Stock Market Reviews

RVPH (Reviva Pharmaceuticals Holdings, Inc.) News

Get the latest news, insights, and market updates on RVPH (Reviva Pharmaceuticals Holdings, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
  – Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Brilaroxazine improved multiple neuroinflammatory markers reported to enhance efficacy and mitigate side effects – – Virtual investor webcast today at 8:00 a.m. EDT – CUPERTINO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a
  Jun 2, 2025 - $RVPH
• RVPH: 1Q:25 Results
  By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported 1Q:25 results updating investors on the progress of the open-label extension (OLE) trial reporting it as complete and targeting release of the full data set before the end of the second quarter. The company also expects to begin the second registrational Phase III
  May 22, 2025 - $RVPH
• Reviva to Participate in Upcoming Investor Conferences in May 2025
  CUPERTINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following upcoming investor conferences. Benchmark Healthcare House Ca
  May 20, 2025 - $RVPH
• Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights
  – 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment – – Full data set from RECOVER OLE highlighting clinical response, safety, efficacy, adherence, and biomarker data expected in Q2 2025 – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 – CUPERTINO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Revi
  May 15, 2025 - $RVPH
• Reviva to Participate in the A.G.P. Healthcare Company Showcase
  CUPERTINO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the A.G.P. Healthcare Company Showcase, taking place vi
  May 13, 2025 - $RVPH